Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants

Tata 1mg optimises e-commerce operations with Unicommerce

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

Sun Pharma gets FDA approval for new device to treat skin disease

Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India

Lupin receives USFDA approval for Rivaroxaban Tablets

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25